Table 1. Clinical and histologic prognostic factors and IMP-3 expression.
| IMP-3 expression | ||||
|---|---|---|---|---|
| Characteristic | Total | ≥10% of tumor cells, n (%) | OR (95% CI) | P-value |
| Age (years) | ||||
| <65 | 41 | 28 (68.3%) | 1.00 | |
| ≥65 | 52 | 42 (80.8%) | 1.95 (0.75–5.06) | 0.170 |
| Sex | ||||
| Female | 45 | 30 (66.7%) | 1.00 | |
| Male | 48 | 40 (83.3%) | 2.50 (0.94–6.66) | 0.067 |
| Ulceration | ||||
| No | 59 | 44 (74.6%) | 1.00 | |
| Yes | 34 | 26 (76.5%) | 1.11 (0.41–2.97) | 0.839 |
| Tumor thickness (mm) | ||||
| ≤1 | 18 | 9 (50%) | 1.00 | |
| 1.01–2.00 | 29 | 21 (72.4%) | 2.63 (0.77–9) | 0.125a |
| 2.01–4.00 | 18 | 16 (88.9%) | 8 (1.41–45.4) | 0.019a |
| >4 | 28 | 24 (85.7%) | 6 (1.47–24.45) | 0.012a |
| Lymph node metastasis | ||||
| No | 73 | 52 (71.2%) | 1.00 | |
| Yes | 20 | 18 (90%) | 3.63 (0.77–17.05) | 0.102 |
| BRAF/NRAS mutationsb | ||||
| No | 65 | 49 (75.4%) | 1.00 | |
| Yes | 22 | 19 (86.4%) | 2.07 (0.54–7.91) | 0.289 |
| Upper-extremity location | ||||
| No | 79 | 46 (74.7%) | 1.00 | |
| Yes | 14 | 11 (78.6%) | 1.24 (0.32–4.91) | 0.756 |
| AJCC stage at diagnosis | ||||
| I | 33 | 19 (57.6%) | 1.00 | |
| II | 38 | 31 (81.6%) | 3.26 (1.12–9.53) | 0.031c |
| III | 17 | 16 (94.1%) | 11.79 (1.39–99.7) | 0.024c |
| IV | 5 | 4 (80%) | 2.95 (0.30–29.32) | 0.357c |
AJCC, American Joint Committee on Cancer; CI, confidence intervals; IMP-3, IGF II mRNA-binding protein 3; OR, odds ratio.
a Comparison of specified group with thickness ≤1 mm.
b Six patients had missing BRAF/NRAS mutations data.
c Comparison of specified group with stage I.